Advertisement

PharmacoEconomics

, Volume 22, Issue 1, pp 43–53 | Cite as

A multicentre study of patient survival, disability, quality of life and cost of care

Among patients with AIDS in Northern Italy
  • Andrea Tramarin
  • Stefano Campostrini
  • Maarten J. Postma
  • Guido Calleri
  • Keith Tolley
  • Nicoletta Parise
  • Fausto de Lalla
Original Research Article

Abstract

Objective: To describe the epidemiological, clinical and economic changes that occurred in the HIV epidemic in Italy prior to and after the introduction of highly active antiretroviral therapy (HAART).

Design: A prospective, observational, multicentre case-control study was conducted comparing data, collected over 6 months, from an AIDS cohort in 1998 with that of a cohort in 1994. Out of 77 patients with AIDS in the 1998 cohort, 74 survived. These 74 patients were matched for severity of illness with 74 patient survivors from the 1994 cohort to enable valid comparisons of mortality, disability-dependency (DD), health-related QOL (HR-QOL), and direct costs.

Results: Overall, a considerable difference was observed in mortality (33.8% in 1994 vs 3.9% in 1998) between unmatched patients of the two cohorts. As for matched patients, the number of hospital admissions was 1.7 in 1994 and 0.8 in 1998; the average length of stay was 28.1 days in 1994 and 12.6 days in 1998. The direct cost per patient per year was €15 390 and €11 465 for the 1994 and 1998 cohorts, respectively (1999 values). The 1998 patient cohort had significantly better HR-QOL at 6 months in two domains of the instrument used (emotional reaction and energy) and the percentage of totally dependent patients was significantly lower compared with the 1994 cohort (1.4% vs 6.8%).

Conclusions: This is the first study to present a comprehensive comparison of direct costs, DD and HR-QOL of patients with AIDS between two time periods. The use of a case-control design has enabled changes in costs and outcomes to be linked to the introduction of HAART in Italy in 1997.

Keywords

Nottingham Health Profile Observational Study Design Total Direct Medical Cost Pragmatic Randomise Control Trial Unmatched Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The 1998 study (The Palladio study) has been partly supported by Merck Sharp & Dohme S. p. A., Italy. The authors have no conflicts of interest that are directly or indirectly relevant to the content of this manuscript.

The authors gratefully acknowledge the contributions of Dr Dongping Yin (MSD S.p.A.) for his assistance and JM Bos (GUIDE/GRIP) for the critical review of the paper.

References

  1. 1.
    Hanvelt RA, Ruedy NS, Hogg RS, et al. Indirect costs of HIV/AIDS mortality in Canada. AIDS 1994; 8: 7–11CrossRefGoogle Scholar
  2. 2.
    Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalisations in 10 French AIDS reference centres. AIDS 1997; 11: 101–5CrossRefGoogle Scholar
  3. 3.
    Patella FJ, Delanee KM, Moorman AC, et al. Declining mor-bidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853–60CrossRefGoogle Scholar
  4. 4.
    Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999; 13: 963–9PubMedCrossRefGoogle Scholar
  5. 5.
    Keiser P, Kvanli MB, Turner D, et al. Protease inhibitors therapy is associated with decreased with HIV related health care costs in men treated at a Veteran Administration Hospital. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 28–33PubMedCrossRefGoogle Scholar
  6. 6.
    Perdue BE, Weidle PJ, Everson-Mays, et al. Evaluating the cost of medications for ambulatory HIV-infected persons associated with landmark changes in antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 4: 354–60CrossRefGoogle Scholar
  7. 7.
    Lapins D, Hamel E, Barret J, et al. Cost of HIV care in the era of combination therapy [abstract PO 460–737]. 39th ICAAC; 1999 Sep 26–29; San FranciscoGoogle Scholar
  8. 8.
    Moore RD. Cost-effectiveness of combination HIV therapy: 3 year later. Pharmacoeconomics 2000; 17 (4): 325–30PubMedCrossRefGoogle Scholar
  9. 9.
    Grimes DA, Schultz KF. Bias and causal associations in obser-vational research. Lancet 2002; 359: 248–52PubMedCrossRefGoogle Scholar
  10. 10.
    Tramarin A, Tolley K, Campostrini S, et al. Efficiency and rationality in the planning of health care for people with AIDS: an application of the balance of care approach. AIDS 1997; 11: 809–16PubMedCrossRefGoogle Scholar
  11. 11.
    Aggiornamento dei casi di AIDS notificati in Italia al 30 Giugno 2000. Notiziario dell’Istituto Superiore di SanitA 2000; 13 (11): 1–12Google Scholar
  12. 12.
    Alonso J, Hunt S, Niero M, and the European Group for Quality of Life and Health Measurement. European guide to the Nottingham health profile. D Bucquet, editor. France: Montpellier, 1992Google Scholar
  13. 13.
    Wilking D, Thompson C. User’s guide to dependency measures for elderly people: social service monograph 1989. Sheffield: Joint Unit for Social Services Research, University of Sheffield, 1989Google Scholar
  14. 14.
    Postma MJ, Jager JC, Ruwaard D, et al. Disease-staging for modelling current and future health-care impact of disease; illustrations for diabetes mellitus and AIDS. Health Policy 1998; 43: 45–54PubMedCrossRefGoogle Scholar
  15. 15.
    Turner BJ, Kelly JV, Ball JK. A severity classification system for AIDS hospitalisations. Med Care 1989; 27: 423–36PubMedCrossRefGoogle Scholar
  16. 16.
    Kelly JV, Ball JK, Turner BJ. Duration and costs of AIDS hospitalisation in new york: variations by patients severity illness and hospital type. Med Care 1989; 27: 1085–98PubMedCrossRefGoogle Scholar
  17. 17.
    Scitovsky AA. Studying the cost of HIV-related illnesses: reflection on the moving target. Milbank Q 1989; 673: 18–44Google Scholar
  18. 18.
    Miners AH, Sabin CA, Trueman P, et al. Assessing the costeffectiveness of HAART for adults with HIV in England. HIV Med 2001; 2 (1): 52–8PubMedCrossRefGoogle Scholar
  19. 19.
    Cook J, Dasbach E, Coplan P, et al. Modelling the long term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. AIDS Res Hum Retroviruses 1999; 15 (6): 499–508PubMedCrossRefGoogle Scholar
  20. 20.
    Paul S, Gilbert HM, Ziecheck W, et al. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999 Feb 25; 13 (3): 415–8PubMedCrossRefGoogle Scholar
  21. 21.
    Garanttini L, Tediosis F, Di Cintio E, et al. Resource utilisation and hospital costs of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care 2001; 13 (6): 733–41CrossRefGoogle Scholar
  22. 22.
    Johnson AM, Shergold C, Haekins A, et al. Patterns of hospital care for patients with HIV infection and AIDS. J Epidemiol Community Health 1993; 47: 232–7PubMedCrossRefGoogle Scholar
  23. 23.
    Beck EJ, Kennelly J, McKevitt J, et al. Changing use of hospital services and costs at a London AIDS referral centre. AIDS 1994; 8: 367–77PubMedCrossRefGoogle Scholar
  24. 24.
    Taroni F, Anemona A per it gruppo di Studio AN. CO. L’assistenza ospedaliera per i pazienti con AIDS in Italia. GIAIDS 1993; 1: 2–15Google Scholar
  25. 25.
    Torti C, Casari S, Palvarini L, et al. Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmacoeconomic implications in a population-based setting. Health Policy 2003 Sep; 65 (3): 261–7PubMedCrossRefGoogle Scholar
  26. 26.
    Nieuwkerk PT, Gisolf EH, Colebunders R, et al. Quality of life in asymptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. AIDS 2000; 14: 181–2PubMedCrossRefGoogle Scholar
  27. 27.
    Revicky DA, Moyle G, Stellbrink HJ, et al. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine and saquinavir-zalcitabine-zidovudinetherapy for HIV-infected adults with CD4 cell count between 50 and 350 per cubic millimeter. AIDS 1999; 13: 851–8CrossRefGoogle Scholar
  28. 28.
    Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996; 312: 1215–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Andrea Tramarin
    • 1
  • Stefano Campostrini
    • 2
  • Maarten J. Postma
    • 3
  • Guido Calleri
    • 4
  • Keith Tolley
    • 5
  • Nicoletta Parise
    • 2
  • Fausto de Lalla
    • 1
  1. 1.Infectious Diseases DepartmentSan Bortolo HospitalVicenzaItaly
  2. 2.Department of Statistical SciencePadua UniversityPaduaItaly
  3. 3.Groningen University Institute for Drug Exploration/University of Groningen Research Institute of Pharmacy (GUIDE/GRIP)GroningenThe Netherlands
  4. 4.Department of Infections DiseasesAmedeo di Savoia HospitalTurinItaly
  5. 5.Health Economics Facility, Health Service Management CenterUniversity of BirminghamBirminghamUK

Personalised recommendations